Journals / MN Kardiyoloji / 2006 / Cilt: 13 - Sayı: 4

Current practice of secondary prevention of cardiovascular disease under the scope of AHA/ ACC 2006 guideliness

AHA/ACC 2006 kılavuzu ışığında kardiyovasküler hastalıkların ikincil korumasında güncel yaklaşımlar

Pages
281–285
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This report outlines the main changes in the secondary prevention guidelines.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Evidence from clinical trials support the use of pharmacological and non- pharmacological therapies in the secondary prevention of coronary artery disease.
📊
Key Findings & Data:The American Heart Association (AHA) and American College of Cardiology (ACC) updated the guidelines regarding risk reduction strategies for patients with coronary and other atherosclerotic vascular disease based upon the new study results.
💡
Conclusion & Impact:This report outlines the main changes in the secondary prevention guidelines.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Amerikan Kalp Birliği · Kalp damar hastalıkları · Lipidler

Abstract

Evidence from clinical trials support the use of pharmacological and non- pharmacological therapies in the secondary prevention of coronary artery disease. The American Heart Association (AHA) and American College of Cardiology (ACC) updated the guidelines regarding risk reduction strategies for patients with coronary and other atherosclerotic vascular disease based upon the new study results. The updated guideline recommended a target low density lipoprotein cholesterol level of less than 100 mg/ dl for all patients with coronary artery disease and other forms of atherosclerotic vascular disease. Also, it is deemed “reasonable” to bring low density lipoprotein cholesterol levels to below 70 mg/ dl in these patients. The next modification in the guideline is the recommendation that expands the use of angiotensin converting enzyme inhibitors. It is considered “reasonable” to use angiotensin converting enzyme inhibitors in patients with atherosclerosis and normal left ventricular systolic function. The updated guidelines also recommend to reduce the dose of aspirin for chronic therapy. The changes regarding the use of aspirin and clopidogrel following percutaneous coronary intervention reflect “AHA/ ACC Percutaneous Coronary Intervention” guidelines. For the first time, the guidelines recommend influenza vaccination for patients with chronic cardiovascular disease. This report outlines the main changes in the secondary prevention guidelines.

Özet

Çalışmalardan elde edilen kanıtlar, koroner arter hastalığında ikincil koruma amacıyla farmakolojik ve farmakolojik olmayan tedavilerin kullanımını desteklemektedir. “American Heart Association (AHA)/ American College of Cardiology (ACC)” koroner ve diğer aterosklerotik vasküler hastalıklarda risk azaltılması stratejilerine yönelik kılavuzunu yeni çalışma sonuçlarını esas alarak yakın zamanda güncelledi. Güncellenmiş kılavuzda, koroner arter hastalığı ve diğer aterosklerotik hastalıklara sahip olan bütün hastalarda hedef düşük dansiteli kolesterol seviyesinin 100 mg/ dl’ nin altında olması önerilirken, bu hastalarda düşük dansiteli kolesterolü 70 mg/ dl’ nin altına indirmenin mantıklı olduğu belirtilmektedir. Kılavuzda yer alan yeni bir değişiklik ise, anjiyotensin dönüştürücü enzim inhibitörü kullanımı sınırlarının genişletilmesidir. Ateroskleroz ve normal sol ventrikül sistolik fonksiyonuna sahip hastalarda anjiyotensin dönüştürücü enzim inhibitörü kullanımının mantıklı olabileceği belirtilmiştir. Güncellenmiş kılavuz ayrıca aspirinin kronik tedavideki kullanım dozunun düşürülmesi yönünde öneride bulunurken, perkütan koroner girişim sonrası aspirin ve klopidogrel kullanımı ile ilgili yapılan öneriler “AHA/ ACC Perkütan Koroner Girişim” kılavuzunu yansıtmaktadır. Ek olarak, ilk defa bir kılavuzda kronik kardiyovasküler hastalıkta influenza aşısı önerilmektedir. Bu yazıda, ikincil koruma kılavuzu önerilerinde yapılan değişiklikler ana hatlarıyla özetlenmektedir.

🔖

Cite This Article

SELÇUK, H., SELÇUK, M. T. (2006). Current practice of secondary prevention of cardiovascular disease under the scope of AHA/ ACC 2006 guideliness. MN Kardiyoloji, Cilt: 13 - Sayı: 4, 281–285. https://ajindex.com/articles/299114

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006; 113:2363-72.
  2. Smith SC Jr, Blair SN, Bonow RO, et al. AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 2001; 38:1581-3.
  3. Padwal R, Straus SE, McAlister FA. Evidence based management of hypertension. Cardiovascular risk factors and their effects on the decision to treat hypertension: evidence based review. BMJ 2001; 322:977-80. S Investigators: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
  4. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001-1009. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1349-1357.
  5. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285:1711 -1718. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22. Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: prospective meta analysis of data from 90.056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-1278.
  6. Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-1504.
  7. Shepherd J, Blauw GJ, Murphy MB, et al. PROSPER study group. PROspective Study of Pravast